Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib Publication Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…Dorottya Gui-Bodnar2026 年 5 月 28 日
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators Webinar The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators Certara2026 年 5 月 26 日
Simcyp Focused Workshop: DDI (Predicting and evaluating complex DDIs) Japan Live Events Simcyp Focused Workshop: DDI (Predicting and evaluating complex DDIs) Japan Certara2026 年 5 月 20 日
Simcyp Focus Group Workshop: Biopharmaceutics Applications of PBPK Modelling – Japan Live Events Simcyp Focus Group Workshop: Biopharmaceutics Applications of PBPK Modelling – Japan Certara2026 年 5 月 19 日
How to Leverage PBPK Modeling and Simulation in Drug Research and Development Guide How to Leverage PBPK Modeling and Simulation in Drug Research and Development Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…Certara2026 年 5 月 12 日
Minimize risk when preparing for hepatic impairment studies Webinar Minimize risk when preparing for hepatic impairment studies Certara2026 年 5 月 12 日
PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials Press Coverage PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials The FDA is shifting toward approving drugs based on a single pivotal trial supported by…Certara2026 年 5 月 12 日
The one-trial era: what the FDA’s shift signals for the future of drug development Press Coverage The one-trial era: what the FDA’s shift signals for the future of drug development The FDA is shifting toward approving drugs based on a single pivotal trial supported by…Certara2026 年 5 月 6 日
How Pharma Can Transition to Non-animal Studies for Investigational Drugs Blog 如何实现药品研发中的动物实验向非动物实验的转型 Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…Certara2026 年 5 月 5 日
From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development Blog From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…Certara2026 年 4 月 28 日